



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 17 2009

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

The attached documents relate to the patent term extension application for U.S. Patent No. 6,204,257, which was filed on February 6, 2009, under 35 U.S.C. § 156.

Applicant is fulfilling their duty of disclosure pursuant to 37 C.F.R. § 1.765 by submitting information to the USPTO and FDA indicating that more than one application for patent term extension was filed for the single regulatory review period for the human drug product, LUSEDRA™, NDA No. 02-2244.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Christopher N. Sipes
Covington & Burling LLP
1201 Pennsylvania Ave., NW
Washington, DC 20004-2401